Please wait...

Description

Warning, this event was expired!

Wednesday, February 3, 2021 at 10:30-11:30 am ET | 3:30-4:30 pm GMT.

Blooloop and Christie present a live discussion: “How can far-UVC light help attractions battle COVID-19?” on 3 February. New far-UVC light disinfection technology could be a game changer for the attractions business.

Join us on 3 February, 3:30pm GMT to find out how far-UVC light disinfection could help visitor attractions to reopen, and to future proof venues.

The pandemic has resulted in visitor attractions closing around the world. With vaccines now coming online the end of lockdown seems in sight. But is a vaccine a silver bullet? We are already seeing new mutations of the COVID-19 virus, even before the first vaccine has been rolled out. And what about future threats?

In order to regain consumer confidence in entering location based entertainment venues, effective disinfection will play a key role. Far-UVC light disinfection is a new technology that can be instrumental in reopening visitor attractions now. It also provides a solution capable of addressing new viruses and “superbugs” in the future.

Speakers

Martin Howe has over 35 years’ experience introducing and delivering new technologies to market across a range of demanding applications around the world. He is a creative ‘techie’, an ideas generator, a big picture thinker and determined problem solver with the ability to translate ambitious goals into a structured plan and hands-on delivery.

Brent Peckover is the Director of Industrial Applications at Christie, focusing on launching innovative ideas outside of traditional markets and applications. He is spearheading the design and development activities for Christie® CounterAct™ with patented Care222® technology commercial ultraviolet disinfection fixtures.

Your compare list

Compare
REMOVE ALL
COMPARE
0
Select your currency
EUR Euro

Global search

Touring Stories newsletter

Sign Up For Updates

Stay tuned for announcements and receive our Touring Stories newsletter.